Protein Science, Vol 7, Issue 6 1317-1325, Copyright © 1998 by Cold Spring Harbor Laboratory Press

ARTICLE

Structural investigation of the A domains of human blood coagulation factor V by molecular modeling

B. O. VILLOUTREIX and B. DAHLBACK
Lund University, The Wallenberg Laboratory, Department of Clinical Chemistry, University Hospital, Malmo, S-205 02 Malmo, Sweden

Factor V (FV) is a large (2,196 amino acids) nonenzymatic cofactor in the coagulation cascade with a domain organization (A1-A2-B-A3-C1-C2) similar to the one of factor VIII (FVIII). FV is activated to factor Va (FVa) by thrombin, which cleaves away the B domain leaving a heterodimeric structure composed of a heavy chain (A1-A2) and a light chain (A3-C1-C2). Activated protein C (APC), together with its cofactor protein S (PS), inhibits the coagulation cascade via limited proteolysis of FVa and FVIIIa (APC cleaves FVa at residues R306, R506, and R679). The A domains of FV and FVIII share important sequence identity with the plasma copper-binding protein ceruloplasmin (CP). The X-ray structure of CP and theoretical models for FVIII have been recently reported. This information allowed us to build a theoretical model (994 residues) for the A domains of human FV/FVa (residues 1-656 and 1546-1883). Structural analysis of the FV model indicates that: (a) the three A domains are arranged in a triangular fashion as in the case of CP and the organization of these domains should remain essentially the same before and after activation; (b) a Type II copper ion is located at the A1-A3 interface; (c) residues R306 and R506 (cleavage sites for APC) are both solvent exposed; (d) residues 1667-1765 within the A3 domain, expected to interact with the membrane, are essentially buried; (e) APC does not bind to FVa residues 1865-1874. Several other features of factor V/Va, like the R506Q and A221V mutations; factor Xa (FXa) and human neutrophil elastase (HNE) cleavages; protein S, prothrombin and FXa binding, are also investigated.
CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Steen, S. Tran, L. Autin, B. O. Villoutreix, A.-L. Tholander, and B. Dahlback Mapping of the Factor Xa Binding Site on Factor Va by Site-directed Mutagenesis J. Biol. Chem., July 25, 2008; 283(30): 20805 - 20812. [Abstract] [Full Text] [PDF]

				B. Dahlback and B. O. Villoutreix Regulation of Blood Coagulation by the Protein C Anticoagulant Pathway: Novel Insights Into Structure-Function Relationships and Molecular Recognition Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1311 - 1320. [Abstract] [Full Text] [PDF]

				T. E. Adams, M. F. Hockin, K. G. Mann, and S. J. Everse The crystal structure of activated protein C-inactivated bovine factor Va: Implications for cofactor function PNAS, June 15, 2004; 101(24): 8918 - 8923. [Abstract] [Full Text] [PDF]

				M. Steen, E. A. Norstrom, A.-L. Tholander, P. H. B. Bolton-Maggs, A. Mumford, J. H. McVey, E. G. D. Tuddenham, and B. Dahlback Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis Blood, May 1, 2004; 103(9): 3381 - 3387. [Abstract] [Full Text] [PDF]

				M. C. Montefusco, S. Duga, R. Asselta, M. Malcovati, F. Peyvandi, E. Santagostino, P. M. Mannucci, and M. L. Tenchini Clinical and molecular characterization of 6 patients affected by severe deficiency of coagulation factor V: broadening of the mutational spectrum of factor V gene and in vitro analysis of the newly identified missense mutations Blood, November 1, 2003; 102(9): 3210 - 3216. [Abstract] [Full Text] [PDF]

				M. Steen, M. Miteva, B. O. Villoutreix, T. Yamazaki, and B. Dahlback Factor V New Brunswick: Ala221Val associated with FV deficiency reproduced in vitro and functionally characterized Blood, August 15, 2003; 102(4): 1316 - 1322. [Abstract] [Full Text] [PDF]

				K. G. Mann and M. Kalafatis Factor V: a combination of Dr Jekyll and Mr Hyde Blood, January 1, 2003; 101(1): 20 - 30. [Full Text] [PDF]

				M. Steen, B. O. Villoutreix, E. A. Norstrom, T. Yamazaki, and B. Dahlback Defining the Factor Xa-binding Site on Factor Va by Site-directed Glycosylation J. Biol. Chem., December 13, 2002; 277(51): 50022 - 50029. [Abstract] [Full Text] [PDF]

				M. Steen and B. Dahlback Thrombin-mediated Proteolysis of Factor V Resulting in Gradual B-domain Release and Exposure of the Factor Xa-binding Site J. Biol. Chem., October 4, 2002; 277(41): 38424 - 38430. [Abstract] [Full Text] [PDF]

				A. J. Gale, X. Xu, J.-L. Pellequer, E. D. Getzoff, and J. H. Griffin Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C Protein Sci., September 1, 2002; 11(9): 2091 - 2101. [Abstract] [Full Text] [PDF]

				G. A.F. Nicolaes and B. Dahlback Factor V and Thrombotic Disease: Description of a Janus-Faced Protein Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 530 - 538. [Abstract] [Full Text] [PDF]

				C. A. Curat, M. Eck, X. Dervillez, and W. F. Vogel Mapping of Epitopes in Discoidin Domain Receptor 1 Critical for Collagen Binding J. Biol. Chem., November 30, 2001; 276(49): 45952 - 45958. [Abstract] [Full Text] [PDF]

				R. van Wijk, K. Nieuwenhuis, M. van den Berg, E. G. Huizinga, B. B. van der Meijden, R. J. Kraaijenhagen, and W. W. van Solinge Five novel mutations in the gene for human blood coagulation factor V associated with type I factor V deficiency Blood, July 15, 2001; 98(2): 358 - 367. [Abstract] [Full Text] [PDF]

				E. Castoldi, P. Simioni, M. Kalafatis, B. Lunghi, D. Tormene, D. Girelli, A. Girolami, and F. Bernardi Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family Blood, August 15, 2000; 96(4): 1443 - 1448. [Abstract] [Full Text] [PDF]

				B. O. Villoutreix, A. M. Blom, and B. Dahlback Structural prediction and analysis of endothelial cell protein C/activated protein C receptor Protein Eng. Des. Sel., October 1, 1999; 12(10): 833 - 840. [Abstract] [Full Text] [PDF]

				E. Thorelli, R. J. Kaufman, and B. Dahlback Cleavage of Factor V at Arg 506 by Activated Protein C and the Expression of Anticoagulant Activity of Factor V Blood, April 15, 1999; 93(8): 2552 - 2558. [Abstract] [Full Text] [PDF]

				A. R. Zeibdawi and E. L. G. Pryzdial Mechanism of Factor Va Inactivation by Plasmin. LOSS OF A2 AND A3 DOMAINS FROM A Ca2+-DEPENDENT COMPLEX OF FRAGMENTS BOUND TO PHOSPHOLIPID J. Biol. Chem., June 1, 2001; 276(23): 19929 - 19936. [Abstract] [Full Text] [PDF]

				M. Kalafatis and K. G. Mann The Role of the Membrane in the Inactivation of Factor Va by Plasmin. AMINO ACID REGION 307-348 OF FACTOR V PLAYS A CRITICAL ROLE IN FACTOR Va COFACTOR FUNCTION J. Biol. Chem., May 18, 2001; 276(21): 18614 - 18623. [Abstract] [Full Text] [PDF]

				U. Friedrich, G. A.F. Nicolaes, B. O. Villoutreix, and B. Dahlback Secondary Substrate-binding Exosite in the Serine Protease Domain of Activated Protein C Important for Cleavage at Arg-506 but Not at Arg-306 in Factor Va J. Biol. Chem., June 15, 2001; 276(25): 23105 - 23108. [Abstract] [Full Text] [PDF]

				G. A.F. Nicolaes and B. Dahlback Factor V and Thrombotic Disease: Description of a Janus-Faced Protein Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 530 - 538. [Abstract] [Full Text] [PDF]